57P Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in advanced biliary tract cancer (BTC)

L Antonuzzo,J.E Cundom,J Xiong,D-Y Oh,M Petrova,H Takahashi,K Heider,G.M Vaccaro,M Holmblad,R Gillmore,S-S Yang,N Rokutanda,J.O Park,A Sookprasert

doi:10.1016/j.annonc.2022.07.085

57P Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in advanced biliary tract cancer (BTC)

L Antonuzzo, J.E Cundom + Show 12 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.085

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
Citations: 2	License type: publisher-specific-oa

#Advanced Biliary Tract Cancer #Immune Checkpoint Inhibitor + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In TOPAZ-1 (NCT03875235), D + GC significantly improved overall survival (OS) vs PBO + GC for patients (pts) with advanced BTC (Oh et al. J Clin Oncol 2022;40(suppl. 4): Abs 378). D (immune checkpoint inhibitor) may cause imAEs; imAEs have been associated with improved OS (Zhou et al. BMC Med 2020;18:87).

Full Text